Targeting the JNK Pathway for Therapeutic Benefit in CNS Disease

Donna Bozyczko‐Coyne, Robert L. Hudkins(State Street (United States)), Michael S. Saporito(Teva Pharmaceuticals (United States))

Current Drug Targets - CNS & Neurological Disorders

February 1, 2002

10.2174/1568007023339472

Cited by 69

Related Papers

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

|ACS Chemical Neuroscience|2011|436

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

|PubMed|2003|124

Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives

|Journal of Medicinal Chemistry|1997|120

Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

|Expert Opinion on Drug Discovery|2016|113

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

|Molecular Cancer Therapeutics|2007|112